8. INTANGIBLE AND OTHER NON-CURRENT ASSETS

Intangible and other non-current assets consist of the following (in thousands):


	June 30, 2018						December 31, 2017
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
PANCREAZE license (1)	$	141,895	$	(1,183)	$	140,712	$	—	$	—	$	—
Janssen patents (2)		3,050		(2,416)		634		3,050		(2,235)		815
Other non-current assets		199		—		199		199		—		199
Total	$	145,144	$	(3,599)	$	141,545	$	3,249	$	(2,235)	$	1,014

_________________

(1)

In June 2018, the Company acquired the rights to license PANCREAZE in the U.S. and Canada, as described further in Note 12. The rights are being amortized over their estimated useful life of 10 years using the straight-line method.

(2)

In September 2014, the Company acquired certain patents relating to Qsymia from Janssen Pharmaceuticals, approximately $3.1 million of which was recorded as an intangible asset. The patents are being amortized over their estimated useful life of 5.5 years using the straight-line method.

Other non-current assets primarily consist of real estate deposits. Amortization of intangible assets was $1.3 million and $1.4 million for the three and six months ended June 30, 2018, respectively. Future expected amortization expenses for intangible assets as of June 30, 2018 are as follows (in thousands):


2018 (remainder)	$	7,276
2019		14,552
2020		14,280
2021		14,190
2022		14,190
Thereafter		76,858
Total	$	141,346